Please select the option that best describes you:
Topics:
General Internal Medicine • Thrombosis • Hematology • Benign Hematology • Hemostasis/Thrombosis • Primary Care • General Primary Care • Internal Medicine • Women
How would you approach hormone replacement therapy for perimenopause in a patient with increased risk factors for VTE?
Risk factors such as hereditary thrombophilia without personal thrombosis, family history of thrombophilia or thrombosis, etc.
Answer from: Medical Oncologist at Community Practice
Like many medical choices, this decision involves weighing trade-offs—specifically, the risk of venous thromboembolism (VTE) versus the burden of severe menopausal symptoms. If we focus only on VTE risk (and set aside the trade-offs related to menopausal symptoms and the controversial issue of...
Sign In or Register to read more
Answer from: at Academic Institution
In addition to Dr. @Djulbegovic's answer, the lowest effective dose via the transdermal route is generally felt to be safest. I would highly recommend the 2024 ASH Education Program articles in the category "Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?"